Propofol-remifentanil or propofol-ketamine for burn care in pediatric patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0001113

Enrollment

Registered

2014-05-23

Start date

2014-02-28

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : In the propofol-remifentanil group, propofol 2mg/kg and remifentnil 0.1 ug/kg are administered intravenously, and then remifentanil 0.05 ug/kg/min are continously infused. In the propofol-ketam

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients scheduled for burn care under sedation are included.

Exclusion criteria

Exclusion criteria: Patients are excluded if they have a cardiovascular, cerebrovascular, pulmonary, renal or hepatic disease, or are at risk of aspiration.

Design outcomes

Primary

Measure	Time frame
Sedation score;Recovery time	—

Secondary

Measure	Time frame
the incidence of hypotension, bradycardia, respiratory depression, hypoxia;the requirement of additional drugs;Nausea and vomiting ;restlessness or agitation	—

Countries

Korea, Republic of

Contacts

Public ContactJin-Young Hwang

Seoul Metropolitan Government Seoul National University Boramae Medical Center

mistyblue15@naver.com+82-2-870-2518

Outcome results